Twist Bioscience Company Insiders
| TWST Stock | USD 30.06 1.51 4.78% |
Twist Bioscience employs about 923 people. The company is managed by 17 executives with a total tenure of roughly 42 years, averaging almost 2.0 years of service per executive, having 54.29 employees per reported executive. Breaking down Twist Bioscience's management performance can provide insight into the firm performance.
| Emily Leproust CEO President CEO, Director |
| Patrick Finn President Vice President of Sales and Marketing |
Twist Bioscience Management Team Effectiveness
The company has return on total asset (ROA) of (0.1388) % which means that it has lost $0.1388 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1758) %, meaning that it created substantial loss on money invested by shareholders. Twist Bioscience's management efficiency ratios could be used to measure how well Twist Bioscience manages its routine affairs as well as how well it operates its assets and liabilities.Twist Bioscience Workforce Comparison
Twist Bioscience Corp is rated fourth in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 26,312. Twist Bioscience holds roughly 923 in number of employees claiming about 4% of equities under Health Care industry.
The company has Profit Margin (PM) of (0.24) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.31) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.31. Twist Bioscience Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Twist Bioscience insiders, such as employees or executives, is commonly permitted as long as it does not rely on Twist Bioscience's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Twist Bioscience insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Robert Werner few days ago Disposition of 1016 shares by Robert Werner of Twist Bioscience at 31.4443 subject to Rule 16b-3 | ||
Adam Laponis over a week ago Acquisition by Adam Laponis of 25000 shares of Twist Bioscience subject to Rule 16b-3 | ||
Dennis Cho over a month ago Disposition of 5000 shares by Dennis Cho of Twist Bioscience at 32.718 subject to Rule 16b-3 | ||
Robert Werner over a month ago Disposition of 235 shares by Robert Werner of Twist Bioscience at 25.76 subject to Rule 16b-3 | ||
Dennis Cho over two months ago Disposition of 521 shares by Dennis Cho of Twist Bioscience at 25.964 subject to Rule 16b-3 | ||
Robert Werner over two months ago Disposition of 916 shares by Robert Werner of Twist Bioscience at 41.713 subject to Rule 16b-3 | ||
Blake Katryn over three months ago Insider Trading | ||
Patrick Finn over three months ago Disposition of 229 shares by Patrick Finn of Twist Bioscience at 45.5911 subject to Rule 16b-3 |
Twist Bioscience Notable Stakeholders
A Twist Bioscience stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Twist Bioscience often face trade-offs trying to please all of them. Twist Bioscience's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Twist Bioscience's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Emily Leproust | President CEO, Director | Profile | |
| Patrick Finn | Vice President of Sales and Marketing | Profile | |
| Paula Green | Vice President of Human Resources | Profile | |
| Dennis JD | Chief VP | Profile | |
| Dennis Cho | General VP | Profile | |
| Robert Werner | VP Officer | Profile | |
| William Banyai | GM Development | Profile | |
| Kevin Yankton | VP Officer | Profile | |
| Chet Gandhi | Chief Officer | Profile | |
| Michael Fero | Chief Officer | Profile | |
| Nicole Moreno | Senior Support | Profile | |
| Siyuan Chen | Chief Officer | Profile | |
| Aaron Sato | Chief Officer | Profile | |
| James Thorburn | Chief Officer | Profile | |
| Erin Smith | Sr Policy | Profile | |
| Adam Laponis | Chief Officer | Profile | |
| Angela Bitting | Chief Affairs | Profile |
About Twist Bioscience Management Performance
The success or failure of an entity such as Twist Bioscience Corp often depends on how effective the management is. Twist Bioscience management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Twist management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Twist management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company was incorporated in 2013 and is headquartered in South San Francisco, California. Twist Bioscience operates under Diagnostics Research classification in the United States and is traded on NASDAQ Exchange. It employs 989 people.
Please note, the imprecision that can be found in Twist Bioscience's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Twist Bioscience Corp. Check Twist Bioscience's Beneish M Score to see the likelihood of Twist Bioscience's management manipulating its earnings.
Twist Bioscience Workforce Analysis
Traditionally, organizations such as Twist Bioscience use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Twist Bioscience within its industry.Twist Bioscience Manpower Efficiency
Return on Twist Bioscience Manpower
| Revenue Per Employee | 339.1K | |
| Revenue Per Executive | 18.4M | |
| Net Loss Per Employee | 226.1K | |
| Net Loss Per Executive | 12.3M | |
| Working Capital Per Employee | 298.8K | |
| Working Capital Per Executive | 16.2M |
Additional Tools for Twist Stock Analysis
When running Twist Bioscience's price analysis, check to measure Twist Bioscience's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Twist Bioscience is operating at the current time. Most of Twist Bioscience's value examination focuses on studying past and present price action to predict the probability of Twist Bioscience's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Twist Bioscience's price. Additionally, you may evaluate how the addition of Twist Bioscience to your portfolios can decrease your overall portfolio volatility.